期刊文献+

肺腺癌中微乳头结构临床病理及预后意义的探讨 被引量:8

Prognostic significance of micropapillary pattern in pulmonary adenocarcinoma
原文传递
导出
摘要 目的探讨肺腺癌中微乳头结构对肿瘤侵袭行为及其对预后的影响。方法选择具有完整临床病理及随访资料结果的肺腺癌91例,将病例分成微乳头结构阳性组(41例)和阴性组(50例)。阳性组按照该成分占肿瘤的多少又分成微乳头结构+(占肿瘤的1%~10%),++(占肿瘤的11%~30%),+++(超过肿瘤的30%)。结果总的5年生存率是64.8%。临床分期5年生存率分别为Ⅰ期88.9%、Ⅱ期46.2%、Ⅲ期23.8%。不同临床分期病例间的生存率差异有统计学意义(P=0.000)。微乳头结构含量多少与临床分期、肿瘤大小和5年生存率无关,P值分别是0.065、0.358、0.206。而微乳头结构阳性组和阴性组5年生存率分别是:41.5%和84.0%,P=0.000,且淋巴结转移率前者(65.9%)明显高于后者(20.0%),P=0.000。有无微乳头结构与临床分期和肿瘤大小有关,P值均为0.000,即分期越晚,肿瘤越大,出现此结构的几率越高。而有无微乳头结构与性别、吸烟史无关。同一临床分期中阳性组与阴性组5年生存率分别是:Ⅰ期:78.6%、92.6%(P=0.1548);Ⅱ期:30.0%,100%(P=0.0598);Ⅲ期:17.7%,28.6%(P=0.4045),但差异无统计学意义。结论肺腺癌中微乳头结构成分提示肿瘤高侵袭转移行为,是影响预后的重要因素,该病理形态的出现应提醒临床采取积极治疗措施并密切随访。 Objective To evaluate the prognostic significance of micropapillary pattern (MPP) in adenocareinoma of lung. Methods Ninety-one consecutively excised cases of pulmonary adenocareinoma, including follow-up data, were retrospectively studied. These tumors were divided into 2 major groups: those with MPP and those without MPP. The former was further subdivided according to extent of the micropapillary component, as follows: MPP + (constituting 1% to 10% of the tumor), MPP + + (constituting 11% to 30% of the tumor) and MPP + + + (constituting more than 30% of the tumor). Results The overall 5-year survival rate was 64. 8%. The 5-year survival rates were 88. 9% for stage Ⅰ tumors, 46. 2% for stage Ⅱtumors, and 23. 8% for stage Ⅲ tumor respectively (P =0. 000). The extent of micropapillary component showed no correlation with tumor stage, size and 5-year survival rate ( P = 0.065, 0.358 and 0.206, respectively). On the other hand, the 5-year survival rate was 41.5% for patients in the MPP-positive group ( number = 41 ) and 84. 0% for patients in the MPP-negntive group ( number = 50). The percentage of nodal metastasis in MPP-positive group was also higher than that in MPP-negative group (P = 0. 000 ). In pulmonary adenocareinoma, this characteristic histology correlated with tumor stage and size, but not with patient's gender and smoking history. Within the same stage, the 5-year survival rates of MPP-positive and MPP-negative groups were as follows : for stage Ⅰ, 78.6% versus 92. 6% (P= 0.1548), for stage Ⅱ, 30. 0% versus 100% (P=0.0598), and for stage Ⅲ, 17.7% versus 28. 6% (P = 0. 4045 ). Condusions MPP in primary pulmonary adenocareinoma, even when only constituting a minor component, predicts an aggressive clinical behavior and is associated with poor prognosis. Although it may not be an independent prognostic factor, presence of this histologic pattern should alert elinicians for more active treaiment and closer foollow up.
出处 《中华病理学杂志》 CAS CSCD 北大核心 2006年第3期151-154,共4页 Chinese Journal of Pathology
关键词 肺肿瘤 腺癌 预后 Lung neoplasms Adcnocarcinma Prognosis
  • 相关文献

参考文献18

  • 1Siriaunkgul S,Tavassoli FA.Invasive micropapillary carcinoma of the breast.Mod Pathol,1993,6:660-662.
  • 2Amin MB,Ro JY,el-Sharkawy T,et al.Micropapillary variant of transitional cell carcinoma of the urinary bladder.Histologic pattern resembling ovarian papillary serous carcinoma.Am J Surg Pathol,1994,18:1224-1232.
  • 3Burks RT,Sherman ME,Kurman RJ.Micropapillary serous carcinoma of the ovary.A distinctive low-grade carcinoma related to serous borderline tumors.Am J Surg Pathol,1996,20:1319-1330.
  • 4Nagao T,Gaffey TA,Visscher D,et al.Invasive micropapillary salivary duct carcinoma:a distinct variant with biologic significance.Am J Surg Pathol,2004,28:319-326.
  • 5Luna-More S,Gonzalez B,Acedo C,et al.Invasive micropapillary carcinoma of the breast.A new special type of invasive mammary carcinoma.Pathol Res Prac,1994,190:668-674.
  • 6Nassar H,Wallis T,Andea A,et al.Clinicopathologic analysis of invasive micropapillary differentiation in breast carcinoma.Mod Pathol,2001,14:836-841.
  • 7Zekioglu O,Erhan Y,Ciris M,et al.Invasive micropapillary carcinoma of the breast:high incidence of lymph node metastasis with extranodal extension and its immunohistochemical profile compared with invasive ductal carcinoma.Histopathology,2004,44:18-23.
  • 8American Joint Committee on Cancer.AJCC cancer stageing handbook.5th ed.Philadelphia:Lippincott-Raven,1998.
  • 9Travis WD,Brambilla E,Muller-Hermelink HK,et al.Pathology and genetics of tumours of the lung,pleura,thymus and heart.In:World Health Organization International Classification of Tumors.Lyon:International Agency for Research on Cancer (IARC),2003.35-44.
  • 10Nassar H.Carcinoma with micropapillary morphology:clinical significance and current concepts.Adv Anat Pathol,2004,11:297-303.

同被引文献137

引证文献8

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部